Your browser does not support JavaScript!
Autologous Cell Therapy | Esco VacciXcell

Autologous Cell Therapy

CAR-T Cell Therapy

Aside from bone marrow derived and adipose-derived mesenchymal stem cells, Esco VacciXcell also provides solutions for CAR-T Cell Therapy.

Chimeric Antigen Receptor (CAR) is a new innovative and the first FDA-approved therapy that is used to directly target cancer cells. CARs are engineered receptors that have undergone genetic transfer technologies that allow T cells to recognize and attach to specific antigen on cancer cells.

Unlike chemotherapy, CAR-T cells are unique for they can stay in the body for years, continue to circulate and kill cancer cells.

Autologous Cell Therapy (ACT) is a novel therapeutic approach that uses an individual’s cells, which are cultured, engineered, and expanded ex vivo, and introduce back to the patient. This approach has achieved positive feedbacks for it minimizes risks of immunological adverse reactions, bio- incompatibility and transmission-associated diseases (e.g. GVHD).

Esco VacciXcell offers various solutions that simplify autologous cell therapy processing using bone marrow and adipose-derived mesenchymal stem cells. The CradlePro-Iso is a cell processing system, includes the CelCradle™ bioreactor system, Esco’s CO2 incubator, Esco’s Versati™ centrifuge, and Esco’s Orbicult Shaker; this one-stop system fully encloses the entire autologous cell therapy process in a cGMP isolator. Due to the CelCradle™ system’s high productivity, a single CelCradle™ bottle can produce an adequate number of mesenchymal stem cells (up to 1 billion) for 1 patient.

The CradlePro-Iso is ideal for hospitals or when working with a few patients per run. Esco VacciXcell also offers cell processing centers to cater to a larger number of patients for autologous cell therapy.

Learn more about CradlePro-Iso.

How Is It Done?
  1. Patients (Autologous)/ Donors (Allogeneic) collect T cells through a process called Apheresis.
  2. T cells are isolated and shipped to a processing/ bioengineering facility for manufacturing.
  3. Since T cells don’t recognize cancer cells or cannot fully destroy all of them in the body, they are genetically encoded using viral vectors to express a specific antigen receptors (CARs) that recognize cancer cells.
  4. The newly engineered CAR T cells will undergo expansion, concentration and filtration respectively.
  5. Quality check is strictly enforced before infusion to the patient.
  6. In preparation for the CAR T, patient will receive chemotherapy to lessen T cells and make room for newly-engineered ones.
  7. The infusion can be performed either inpatient or outpatient depending on your diagnosis and type of CAR T therapy prescribed.
  8. The infusion will take about an hour or more and patient will be closely monitored for several hours.

TideXcell supports large-scale LVV production thru efficient cultivation of HEK-293T and subsequent transfection.

For more product information, click HERE